{"transactions":[{"id":687957,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-13T20:33:27.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":64.055,"value":640550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":1870,"source":{"system":"sec-edgar","filing":"0001193125-26-349351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526349351/ownership.xml","form_type":"4"}},{"id":751710,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751709,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751708,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751707,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1416,"price":53.41,"value":75628.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations."}],"balance_after":11870,"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":751706,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:00.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":13286,"source":{"system":"sec-edgar","filing":"0001193125-26-256121","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526256121/ownership.xml","form_type":"4"}},{"id":780808,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-14T01:40:43.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2026-06-01","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001193125-26-222369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526222369/ownership.xml","form_type":"4"}},{"id":780807,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-05-14T01:40:43.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":true,"shares":3500,"price":7.38,"value":25830.0,"ownership":{"direct":true},"balance_after":10641,"source":{"system":"sec-edgar","filing":"0001193125-26-222369","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000119312526222369/ownership.xml","form_type":"4"}},{"id":1119618,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-06-06T21:58:57.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0000950170-25-083321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017025083321/ownership.xml","form_type":"4"}},{"id":1119617,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-06T21:58:57.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":17012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":17012,"derivative":{"exercise_price":30.73,"expiration_date":"2035-06-04","underlying":"Common Shares","underlying_shares":17012},"source":{"system":"sec-edgar","filing":"0000950170-25-083321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017025083321/ownership.xml","form_type":"4"}},{"id":1119616,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-06-06T21:58:57.000Z","date":"2025-06-05","kind":"sale","planned":false,"acquired":false,"shares":3,"price":30.48,"value":91.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account."}],"balance_after":7141,"source":{"system":"sec-edgar","filing":"0000950170-25-083321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017025083321/ownership.xml","form_type":"4"}},{"id":1145361,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-16T21:59:44.000Z","date":"2025-05-14","kind":"exercise","planned":false,"acquired":false,"shares":5144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.57,"expiration_date":"2025-05-20","underlying":"Common Shares","underlying_shares":5144},"source":{"system":"sec-edgar","filing":"0000950170-25-073746","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017025073746/ownership.xml","form_type":"4"}},{"id":1145360,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-05-16T21:59:44.000Z","date":"2025-05-14","kind":"exercise","planned":false,"acquired":true,"shares":5144,"price":12.57,"value":64660.08,"ownership":{"direct":true},"balance_after":7144,"source":{"system":"sec-edgar","filing":"0000950170-25-073746","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017025073746/ownership.xml","form_type":"4"}},{"id":1489988,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T21:42:11.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":15542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders."}],"balance_after":15542,"derivative":{"exercise_price":38.16,"expiration_date":"2034-06-04","underlying":"Common Shares","underlying_shares":15542},"source":{"system":"sec-edgar","filing":"0000950170-24-069464","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017024069464/ownership.xml","form_type":"4"}},{"id":1492555,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1492554,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":3.6,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1492553,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":8.15,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1492552,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1492551,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":141011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":2.35,"underlying":"Common Stock","underlying_shares":141011},"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1492550,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T17:31:40.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the \"Arrangement Agreement\"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (\"Parent\") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act (\"Purchaser\"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the \"Shares\") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the \"Effective Time\"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the \"Cash Consideration\") plus (ii) one contingent value right (each, a \"CVR\") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-068906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068906/ownership.xml","form_type":"4"}},{"id":1586735,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-03-08T22:28:51.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":46.2012,"value":92402.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.20 to $46.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0000950170-24-028788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017024028788/ownership.xml","form_type":"4"}},{"id":1586734,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-03-08T22:28:51.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":46.3025,"value":231512.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.3025 to $46.3675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0000950170-24-028788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017024028788/ownership.xml","form_type":"4"}},{"id":1586733,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-03-08T22:28:51.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":46.25,"value":231250.0,"ownership":{"direct":true},"balance_after":9000,"source":{"system":"sec-edgar","filing":"0000950170-24-028788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017024028788/ownership.xml","form_type":"4"}},{"id":1586732,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-03-08T22:28:51.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":46.45,"value":46450.0,"ownership":{"direct":true},"balance_after":14000,"source":{"system":"sec-edgar","filing":"0000950170-24-028788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017024028788/ownership.xml","form_type":"4"}},{"id":1856003,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T17:07:44.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":4.64,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123037092/doc4.xml","form_type":"4"}},{"id":1869872,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:25:34.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":18475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting."}],"balance_after":18475,"derivative":{"exercise_price":38.96,"expiration_date":"2033-06-01","underlying":"Common Shares","underlying_shares":18475},"source":{"system":"sec-edgar","filing":"0000950170-23-026184","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000095017023026184/ownership.xml","form_type":"4"}},{"id":2188231,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-11T16:19:35.000Z","date":"2022-08-11","kind":"purchase","acquired":true,"shares":44400,"price":2.03,"value":90132.0,"ownership":{"direct":true},"balance_after":56400,"source":{"system":"sec-edgar","filing":"0001209191-22-045421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122045421/doc4.xml","form_type":"4"}},{"id":2219369,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:26:01.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders."}],"balance_after":18000,"derivative":{"exercise_price":30.11,"expiration_date":"2032-06-27","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-039827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000120919122039827/doc4.xml","form_type":"4"}},{"id":2224239,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T19:09:24.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-038770","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122038770/doc4.xml","form_type":"4"}},{"id":2593635,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-23T18:28:03.000Z","date":"2021-08-23","kind":"purchase","acquired":true,"shares":2829,"price":7.985,"value":22589.565,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-21-053000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121053000/doc4.xml","form_type":"4"}},{"id":2595027,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T16:10:12.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":3000,"price":8.05,"value":24150.0,"ownership":{"direct":true},"balance_after":9171,"source":{"system":"sec-edgar","filing":"0000899243-21-033814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924321033814/doc4.xml","form_type":"4"}},{"id":2595026,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T16:10:12.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":171,"price":8.05,"value":1376.55,"ownership":{"direct":true},"balance_after":6171,"source":{"system":"sec-edgar","filing":"0000899243-21-033814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924321033814/doc4.xml","form_type":"4"}},{"id":2600435,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T16:05:12.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":6000,"price":8.1,"value":48600.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000899243-21-033258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924321033258/doc4.xml","form_type":"4"}},{"id":2679491,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T16:15:51.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":8.15,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038573","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121038573/doc4.xml","form_type":"4"}},{"id":2683266,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T01:04:35.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000120919121038063/doc4.xml","form_type":"4"}},{"id":3096774,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:49:30.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 36 equal monthly installments beginning on July 18, 2020."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017886","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017886/doc4.xml","form_type":"4"}},{"id":3096773,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:49:30.000Z","date":"2020-01-19","kind":"grant","acquired":true,"shares":141011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments beginning on February 19, 2020. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis."}],"balance_after":141011,"derivative":{"exercise_price":2.35,"expiration_date":"2030-01-19","underlying":"Non-Voting Common Shares","underlying_shares":141011},"source":{"system":"sec-edgar","filing":"0000899243-20-017886","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017886/doc4.xml","form_type":"4"}},{"id":3127114,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T21:00:51.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":13.11,"expiration_date":"2030-05-31","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-033605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000120919120033605/doc4.xml","form_type":"4"}},{"id":3410900,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T22:33:27.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-050131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000120919119050131/doc4.xml","form_type":"4"}},{"id":3905418,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T20:39:58.000Z","date":"2018-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":6.2,"expiration_date":"2028-06-03","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001171843-18-004455","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000117184318004455/formfour.xml","form_type":"4"}},{"id":4235359,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-08-14T22:05:35.000Z","date":"2017-08-11","kind":"purchase","acquired":true,"shares":15000,"price":2.8178,"value":42267.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.8458, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001171843-17-005067","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000117184317005067/formfour.xml","form_type":"4"}},{"id":4295848,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":23700,"kind":"person","name":"GANNON STEVEN","position":1,"cik":"0001643085","reported_name":"GANNON STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T21:02:47.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":3500,"derivative":{"exercise_price":3.85,"expiration_date":"2027-05-31","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001171843-17-003446","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643085/000117184317003446/formfour.xml","form_type":"4"}}]}